DESOXYCORTICOSTERONE ACETATE


Trade Names	DOCA PERCORTEN
Synonyms	11-deoxycorticosterone 11-deoxycorticosterone acetate 21-hydroxyprogesterone Deoxycorticosterone Deoxycorticosterone acetate Deoxycortone Desoxycorticosterone Desoxycorticosterone acetate Desoxycortone Desoxycortone acetate Doca NSC-11319 NSC-9567 Percorten
Status
Molecule Category	Salt
UNII	6E0A168OB8
EPA CompTox	DTXSID6022894


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	VPGRYOFKCNULNK-ACXQXYJUSA-N
Smiles	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
InChI	InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H32O4
Molecular Weight	372.51
AlogP	4.27
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	3.0
Polar Surface Area	60.44
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	27.0

Pharmacology

Mechanism of Action	Action	Reference
Mineralocorticoid receptor agonist	AGONIST	PubMed DailyMed


Protein: Mineralocorticoid receptor Description: Mineralocorticoid receptor Organism : Homo sapiens P08235 ENSG00000151623

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	89

Cross References

Resources	Reference
ChEBI	34671
ChEMBL	CHEMBL1200542
DrugBank	DB06780
DrugCentral	821
FDA SRS	6E0A168OB8
KEGG	C14554
PubChem	5952
SureChEMBL	SCHEMBL4169
ZINC	ZINC000004428527

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).